An observational study in Opioid Use, Opioid Use Disorder and Alcohol Use Disorder, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Uppsala University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Opioid-Related Disorders with a site in Sweden — 2 open to participants now, 4 under way, none of them phase 3. Opioid-Related Disorders · Sweden.
Among the 13 studies in Opioid-Related Disorders with a site in Sweden, this one is one of 4 that started in 2023, is one of 7 observational ones, and was the 13th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →2 of the 13 studies in Opioid-Related Disorders with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Median enrollment 80 across the 6 interventional studies, 480 across the 7 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 9 most frequent:
Uppsala University is the lead sponsor of 390 studies on the registry; 86 are open to participants now.
Uppsala University has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Opioid-Related Disorders with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063902Uppsala UniversityLong-Term Opioid Therapy in Chronic Non-Cancer Pain: Risks and Benefits | 2027-01-14 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Opioid-Related Disorders with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to translate the COMM (Current opinion misuse measure) form and validate it using the ASI-SR (Addiction severity score-self report)in a Swedish population of pain patients treated with opioids. The secondary aim is to investigate acceptability of the instrument in a Swedish population of pain patients with long-term opioid treatment (LOT).
The tertiary aim is to investigate the prevalence of alcohol and illicit substance use in a Swedish population of pain patients with LOT.
There is no validated instrument for the assessment of early detection of substance use disorder development in swedish language.
In order to address this gap, investigators plan to translate and validate the COMM questionnaire using the ASI-SR in a Swedish population of pain patients undergoing opioid treatment. In addition, study will investigate the prevalence of illicit substance use in this population and compare it to patients who are not receiving opioid treatment. The collection of material (blood) in the Uppsala Biobank for future analysis of neurobiological processes during long-term pain treatment will be performed.
Phase 1:
Translation of the instrument takes place according to the "Patient-Reported Outcome (PRO) Consortium translation process guidelines"and according to guidelines from the company MAPI ResearchTrust, which owns the rights to use of the instrument.
Phase 2: The subsequent phase entails validating the COMM instrument against the ASI-SR in a Swedish sample of patients experiencing long-term pain, in accordance with the "Cosmin guidelines" [40], and involves the following procedures. Firstly, the reliability of the COMM instrument by examining internal consistency, test-retest consistency, standard error of measurement (SEM), and conducting factor analysis with rotation in a Swedish population of patients with long-term pain andlong-term opioid treatment (LOT)will be assessed. Secondly, validity of the COMM instrument with regard to comprehensiveness, scope, user-friendliness, and predictability within this particular population will be investigated. Furthermore, investigators will assess the acceptability of the instrument among the study population. Finally, exploration of the prevalence of substance use alongside LOT in pain patients and compare it with pain patients who do not receive opioid treatment will be performed. Inclusion goal is to recruit 200 research subjects from various healthcare settings, including primary care, specialized pain care, other specialized care (e.g., Endometriosis Center), and addiction care (addiction medicine program for pain patients) for the test group. Additionally, 200 individuals are planned to be recruited from pain centers and primary care for the control group to measure prevalence rates. The control group will consist of patients with long-term pain who are not undergoing opioid treatment. Since the study involves two groups of patients with long-term pain (with and without opioid treatment), research group will inquire separately if participants are willing to provide blood samples for biomarker analysis of pain (O-link panel) and genetic analysis, which will be stored in the biobank for future research on the effects of opioids.
Validation will be conducted using the results of drug and alcohol analysis from salivatests and blood. Each category, as identified by the original COMMinstrument, will be evaluated against the following instruments:
In addition, research subjects will also be asked if they would like to be interviewed by a researcher in connection with their consent. Thirty of the initial research subjects who respond positively will undergo a semi-structured interview, where ease of use will be examined using the "think aloud" method. This involves asking subjects about their thoughts on the forms, including their understanding of the questions, language choices, and any possible negative associations. The interviews will then be reviewed using qualitative content analysis.
Moreover, an extensive assessment will be undertaken, involving the input of 10 esteemed professionals in Sweden who specialize in various fields related to this subject matter, such as pain doctors, addiction medicine doctors, psychologists, behavioral scientists, and others. These experts will be approached to provide their valuable insights by responding to a set of carefully devised questions concerning the evaluation of content validity. Their estimations will serve as the fundamental basis for calculating the Content Validity Index (CVI).
In order to collect and analyze the health data, information from medical records, relevant forms, and laboratory responses are compiled into a study database and then transferred to a statistics program. To ensure internal consistency and reliability, Cronbach's alpha is used, with the expectation that it will be higher than 0.70 at a significance level of p\<0.05. Additionally, the agreement between the two test occasions of COMM is assessed using the intraclass correlation coefficient (ICC). The ICC is classified as satisfactory if below 0.40, good if between 0.40-0.59, and excellent if between 0.60-0.70. The correlation between the results of COMM and the ASI-SR is examined using both the Pearson and Spearman correlation coefficients, which are calculated for the respective clusters of questions in the form. Furthermore, confirmatory factor analysis with rotation is employed to investigate the relationship between different clusters or dimensions of questions that can be identified for correlation purposes. The discriminant validity of ASI-SR composite scores and external validity measures are determined by calculating the intercorrelation matrix between COMM groups of questions, ASI-SR composite scores, and external validation measures. The minimum requirement for correlation is set at >0.40. Statistical processing is conducted using SPSS, SAP, and Amos programs. It should be noted that the qualitative aspect of the study is not covered by the statistical plan. In terms of prevalence estimation, both the test group and the control group will be described using descriptive statistics. The occurrence of addictive drugs, non-prescribed drugs, and measures of alcohol use (PETh) during the last three weeks in both groups will be compared using a chi-square test. Odds analysis will be performed to assess secondary use of illegal substances, parallel dependence on other substances, and drugs and alcohol during the length of the study.
Chronic pain patients (18-75 years old) within Uppsala County treated both in Primary care, Secondary care ( Endometrios center) and Tertiary care ( Pain and Addiction clinic)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Intervention group:
Control group:
Exclusion Criteria:
Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who have been treated with opioids for at least 1 month and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
Diagnostic Test: Current Opioid Misuse Measure (COMM)-SWE · Diagnostic Test: Oral fluid drug test · Diagnostic Test: PETh · Diagnostic Test: ASI-SR · Diagnostic Test: AUDIT · Diagnostic Test: DUDIT · Diagnostic Test: Brief Pain Inventory - BPI · Diagnostic Test: Patient Global Impression of Change PGIC · Diagnostic Test: GAD-7 · Diagnostic Test: Patient Health questionnaire (PHQ9) · Diagnostic Test: DBS - cannabis test · Other: Sample of Blood for later DNA and immunological analysis in future studies
Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week, age 18-75 years, who are not treated with opioids (at inclusion and during the last 3 months) and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
Diagnostic Test: Oral fluid drug test · Diagnostic Test: PETh · Diagnostic Test: DBS - cannabis test · Other: Sample of Blood for later DNA and immunological analysis in future studies
Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
Oral fluid sampling to detect drugs. Analysis with LC-HRMS
Alcohol use detection
Also known as: Phosphatydilethanol in blood
Cross-validation form
Also known as: Addiction Severity Score - Short version
Cross-validation form
Also known as: Alkohol Use Disorder Identification Test
Cross-validation form
Also known as: Drug Use Disorder Identification Test
Cross-validation form
Cross-validation form
Cross-validation form
Also known as: Generalized anxiety disorder 7-items scale
Cross-validation form
cross-validation form
sample collection for future studies
COMM - Current opioid misuse version Swedish version
COMM is based on 17 questions, all of which are answered on a 5-point Likert scale. As the original COMM instrument has identified 5 categories of questions, each area will be assessed against the following instruments: 1. Symptoms and signs of drug abuse (question 1) - AUDIT, DUDIT, ASI-SR, drug and alcohol test 2. Emotional and psychiatric problems (questions 2,5,7,8,13) - ASI-SR, GAD-7, PHQ9 3. Visitor characteristics/patterns (questions 3,12,17) - medical record data 4. Occurrence of untrue statement (doubt/lie/untruth) and drug use (questions 4,6,9,10,11) - medical record data, drug and alcohol tests
Time frame: Baseline
ASI-SR Addiction severity index - short release
This instrument is based on interview questions that are used for addiction monitoring by calculating "composite scores", mathematical score measures that are sensitive to change and that are used for follow-up and research. The scoring measures are produced according to a standardized model from the National Board of Health and Welfare (2017). Each domain is calculated in point measures.
Time frame: Baseline
COMM - 2nd test
COMM is based on 17 questions, all of which are answered on a 5-point Likert scale. For retest consistency.
Time frame: 1 week after baseline
AUDIT Alcohol Use Disorder Identification Test
Scoring system, (0-40)where increase of the points reflects increased risk of problematic alcohol use.
Time frame: Baseline
BPI-Brief Pain Inventory - short form
BPI-SF measures ongoing intensity and impact of pain on different areas of life (eg activity, sleep, well-being). Questions are answered in scale 0-10. From there you can calculate the indexes "Pain Intensity" and "Pain Interference".
Time frame: Baseline
Patient global impression of change - PGI-C
7-grade scale (-3-+3)where the lowest points indicate negative and highest points indicate positive change.
Time frame: Baseline
Drug Use Disorder Identification Test (DUDIT)
Scoring system,(0-44) where increase of the points reflects increased probability of drug abuse syndrome.
Time frame: Baseline
Patient Health Questionnaire PHQ9
Depression Assesment scoring system, (0-15) where \<4 is no need of depression treatment, and \>15 identifies need of pharmacologic or other depression treatment
Time frame: Baseline
Drug detection test - saliva
Analysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard
Time frame: baseline
PETh - Phosphatidylethanol in blood
Test monitoring alcohol consumtionduring last 3 weeks monitoring. Results talking: no alcohol use \< 0.05 microg/l , moderate use 0.05-0.30, regular high. amount use \>30microg/l.
Time frame: baseline
Cannabis in DBS ( Dry blood spott)
Analysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard
Time frame: baseline
Generalized anxiety disorder (GAD-7)[
7-items scale, Summary score (0-21), where severity of anxiety increase with more points: \<5 no anxiety, 6-10 mild, 11-16 moderate, \<17 severe
Time frame: baseline
Descriptive characteristics of the group
Age, sex, level of education, work status is requested in the survey, duration of treatment and pain condition and number of visits to healthcare in the last six months (specifically acute visits), diagnosis for which the preparation is prescribed, preparation and dose and actual amount prescribed in the last 6 months and any signs of overuse or problematic use For evaluating factor structure principal component analyses (PCA) .
Time frame: baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.
Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 24 months is below that.
Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.